How Allgenesis Evaluated Unique Endpoints to Advance its Phase
Allgenesis discuss their collaboration on a recent phase two study for diabetic macular edema (DME). The panelists highlight the importance of imaging and biomarkers in ophthalmology clinical trials and share their experiences working with Voxeleron’s AI technology.
Featuring:
- Tan Nguyen: Vice President of Research and Development at Allgenesis Biotherapeutics.
- Janet Cheatham: Clinical Consultant at Allgenesis. * Sunil Patel: Chief Medical Officer at Allgenesis.
- Daniel Russakoff: Chief Technology Officer at Voxeleron